OncRef

Clinical Trial: NCT03916419

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Washington University School of Medicine
Information Provided By:Washington University School of Medicine
Last Update Posted:2026-10-06

Study Overview

Brief Summary

Building upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent chemoradiation and consolidation immunotherapy for locally advanced non-small cell lung cancer (NSCLC), this prospective, single-arm Phase II clinical trial with safety lead-in will test the feasibility and outcomes of this approach.

Official Title

A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Conditions

Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer

Intervention / Treatment

  • Device: ViewRay MR-Linear Accelerator
  • Radiation: Radiation therapy
  • Drug: Paclitaxel
  • Drug: Carboplatin AUC
  • Biological: Durvalumab

Other Study ID Numbers

  • 201905035

Start Date (Actual)

2019-06-20

Primary Completion Date (Actual)

2025-09-28

Study Completion Date (Actual)

2025-09-28

Enrollment (Actual)

26

Study Type

Interventional

Phase

Phase 2